Please assess the completion status of the following clinical trial:

Trial Title: Home Administration of FluMist by Parents/Caregivers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The primary caregiver must be 18 years of age or older and willing to give written informed consent for study participation~2. The primary caregiver must be the parent or legal guardian of all the children in living in the household~3. All the children in the household who are 2 through 17 years of age must receive their primary care in the clinic~4. All the children in the household who are 2 through 17 years of age must have private insurance that will provide for the cost of influenza vaccination~5. There must be at least one member of the household who is 2 through 17 years of age, presenting for care in the clinic, eligible to receive Live Attenuated Influenza Vaccine (LAIV) and whose primary care giver is willing to administer LAIV to them in the clinic with supervision~6. There must be at least one family member of the household who is 2 through 17 years of age, not presenting for care in the clinic, eligible to receive LAIV and whose primary care giver is willing to administer LAIV to them in the in-home setting~7. There must be a working refrigerator in the household~8. The primary caregiver must have a working telephone number and be willing to be contacted for study follow-up by telephone or e-mail~9. The primary caregiver is available for the entire study period - 12 days following the last dose of LAIV to be administered to a child~10. The primary caregiver must agree to complete a 30 minute post vaccination assessment and an 8 day diary following vaccination for each child receiving LAIV.~Exclusion Criteria:~1. Children in the family receive vaccine through Vaccines for Children program

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- FluMist (Type: EXPERIMENTAL): Subjects receiving vaccine at home

Based on this trial design, predict the completion outcome and termination type (if applicable).